Chronic lung infection due to Pseudomonas aeruginosa is the most feared complication in people with cystic fibrosis.
Neupharma distributes two different antibiotics for the treatment of chronic Pseudomonas aeruginosa infection in Italy, patented by PARI Pharma GmbH:
COLFINAIR 1-2 MIO UI Colistimethate sodium
VANTOBRA 170 mg /1.7 ml Tobramycin sulphate
These drugs are subject to specialist medical prescription.
Vantobra and Colfinair have been designed to be delivered with the same aerosol therapy device, PARI eFlow Rapid. At the same time, two specific nebulizers were also developed based on the characteristics of each of the two molecules and related pharmaceutical forms.
Inside each pack of Colfinair and Vantobra there is a new nebulizer specific for the related drug, which is essential for performing a new cycle of antibiotic therapy at maximum efficiency.
